The article provides a concise summary of the 2021 ESC Heart Failure guidelines, emphasizing new diagnostic algorithms and the addition of SGLT2 inhibitors as class I therapy.
Integrates SGLT2 inhibitors and vericiguat into routine HF care; extends 2021 ESC recommendations across phenotypes.
The article provides a summary of the 2021 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure (CHF). The most significant changes for general practitioners, internists and primary care cardiologists, from our point of view, regards etiology, terminology, as well as algorithms for diagnosing and treating CHF in accordance with phenotypes, new indications to a number of drugs, in particular sodium-glucose cotransporter type 2 inhibitors (dapagliflozin and empagliflozin) with assignment of class I recommended therapy and vericiguat. The article discusses the diagnostic criteria for different heart failure phenotypes, the potential of treating patients with heart failure mildly reduced and preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Ларина et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: